New delayed-release stimulant improves morning ADHD symptoms and all-day functioning

By MARY ANN LIEBERT, INC./GENETIC ENGINEERING NEWS New Rochelle, NY, September 25, 2017–A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in…